Schizophrenia is a debilitating disease that affects approximately 1% of the population. Negative symptoms are among the major determinants of the functional impairment and a significant proportion of patients with negative symptoms will continue to experience these symptoms despite antipsychotic medications. There are promising results in the application of brain stimulation, particularly transcranial direct current stimulation (tDCS), for the reduction of negative symptoms of schizophrenia. However, findings are still controversial. This is a selective review of the literature published between 2011 and 2017 on use of tDCS in treatment of negative symptoms of schizophrenia. We included only randomized controlled trials where schizophrenia and negative symptoms were assessed using any psychometrically validated scale (eg, Positive and Negative Symptoms Scale or Scale for the Assessment of Negative Symptoms). Studies of participants with neurological conditions were excluded, as were those that did not report any symptom outcome variables. Only 5 studies are included. Three studies showed a decrease of negative symptoms. The other studies did not show any therapeutic effects of tDCS in the severity of positive and negative symptoms compared to controls. Our findings suggest that negative symptoms in schizophrenia can be treated with tDCS over the dorsolateral prefrontal cortex, but results are affected by several factors, such as the electrode montage, the concomitant medication, the homogeneity of the sample, the intensity of the tDCS treatment. Further randomized, double-blinded, shamcontrolled studies in large samples are still needed to establish the effectiveness of the tDCS in the treatment of negative symptoms in schizophrenia, but there is the potential for tDCS to become a useful complementary treatment option in this population.
Introduction
Schizophrenia (SCZ) affects approximately 1% of the population and can be considered the most disabling neuropsychiatric disorder. Among the complex clinical picture of SCZ, negative symptoms are among the major determinants of such functional impairment and poor quality of life. Indeed, these symptoms are highly prevalent, are very stable over time and are associated with cognitive impairment. A significant proportion of patients with negative symptoms will continue to experience these symptoms in spite of antipsychotic medication. 1 In a recent review of the literature of negative symptoms, Marder and Galderisi 2 proposed that 5 constructs should be considered as negative symptoms, that is, blunted affect, alogia, anhedonia, asociality, and avolition. Also, they have highlighted that the pathophysiology of persistent negative symptoms is still unknown, and these symptoms remain a major challenge in the treatment of those suffering from the disorder. To date, adjunctive medications to antipsychotic medication or psychosocial interventions have limited benefit on reduction of negative symptoms. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, research is progressively enhancing our understanding of the brain mechanisms that underlie the various symptoms of SCZ.
Neuroimaging findings on negative symptoms of SCZ are still inconsistent; however, an association between negative symptoms and gray matter reductions in the prefrontal cortex is often found. 14, 15 Moreover, even during rest, hypoactivity of the prefrontal cortex, particularly of the left dorsolateral, and of the anterior cingulate regions, has been linked to negative symptoms of SCZ. 16, 17 The striatal dopaminergic hyperactivity is also associated with the negative and positive symptoms of the illness 18 and dysfunctional connectivity between hub regions, such as fronto-thalamic-parietal or frontal-striatal networks, may play a major role in the pathophysiology of the negative symptom spectrum. 19, 20 Treatments that could target these brain regions would be of considerable value and promising therapeutic option for negative symptoms of SCZ. For example, noninvasive brain stimulation to the prefrontal cortex, by means of facilitatory or inhibitory projections, can modulate extrastriatal and mesostriatal dopaminergic pathways, that may contribute to negative symptoms. 22, 23 In this regard, transcranial direct current stimulation (tDCS), a neuromodulatory and noninvasive brain stimulation technique, has been investigated in various neuropsychiatric disorders. 24 tDCS devices delivers a direct low current to the brain through 2 electrodes-anode and cathode-increasing and decreasing cortical excitability. It has been shown to be safe in several experimental and clinical trials 25 and potential therapeutic benefits have been demonstrated in depression, pain disorders, tinnitus, and motor impairment poststroke. 26, 27 The effects of this technique on SCZ have been investigated, with promising results in the reduction of both positive and negative symptoms. Particularly, its action on dopaminergic network is relevant to contribute to the transient diminishing of negative symptoms. 28, 29 However, physiologic studies indicate disrupted plasticity in SCZ, which may reduce the efficacy of tDCS [30] [31] [32] and possibly contribute to negative findings on tDCS studies.
In this selective review, we summarize and critically examine the evidence of randomized controlled trials on the efficacy of tDCS in improving negative symptoms of SCZ.
Methods

Study Design
This is a selective review of the literature published between 2011 and 2017 on use of tDCS in treatment of negative symptoms of SCZ. We decided to focus on years 2011-2017 in order to focus on the most recent data about the efficacy of tDCS in the reduction of negative symptoms. Indeed, for the previous period, there are no studies where the efficacy of tDCS has been studied in SCZ in a specific way and using standardized tests for the evaluation of negative symptoms.
Search Strategy
A comprehensive literature search of the PubMed/MEDLINE, Cochrane Library, the Cumulative Index to Nursing and Allied Health Literature (CINHAL), PsycINFO, ClinicalTrial.gov databases was conducted. A search algorithm based on a combination of the terms: (transcranial direct stimulation) AND (schizophrenia OR negative symptoms); (Tdcs) AND (schizophrenia OR negative symptoms).
The last update of the search was on July 2017.
Selection Criteria
We included only studies where SCZ and negative symptoms were assessed using any psychometrically validated scale (eg, Positive and Negative Symptoms Scale [PANSS] 33 or Scale for the Assessment of Negative Symptoms [SANS] 34 ). Studies of participants with neurological conditions were excluded, as were those that did not report any symptom outcome variables. Studies involving co-interventions were eligible for inclusion if the effects of tDCS per se were discernible. Finally, we have included only studies in which control group was present.
Selection Procedure, Data Extraction, and Data Management
Data on efficacy, acceptability, and tolerability were extracted by 4 authors independently (O.S., M.C.T., D.M., R.A.). Disagreements were resolved in a consensus meeting or by other reviewers (M.P., F.C., S.V.). No language limits were used.
The search algorithm resulted in 56 articles, of which 37 referred to potentially eligible studies. Of these, 31 articles were nonempirical studies, reviews, and commentaries. We found a total pool of 5 studies on use of tDCS in treatment of negative symptoms of SCZ. Figure 1 represents the search strategy with inclusion/exclusion criteria for the studies.
Summary of Findings
We found 5 studies examining the effect of tDCS in randomized double-blind trials in SCZ. Details on the methodologies and results of the studies are shown in Table 1 .
Brunelin et al 35 investigated the efficacy of tDCS in reducing the severity of auditory verbal hallucinations and negative symptoms in adult patients with SCZ and pharmacological treatment resistance (N = 30). The patients were randomly divided to receive 20 minutes of active 2-mA tDCS or sham stimulation twice a day for 5 consecutive days. During the stimulation, the anode was placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the left temporoparietal cortex. To measure the effectiveness of the treatment on the severity of auditory verbal hallucinations was used the Auditory Hallucination Rating Scales (AHRS), 40 whereas the other SCZ symptoms were assessed using the PANSS. 33 Results showed that auditory verbal hallucinations were robustly reduced by tDCS relative to sham stimulation, with a mean diminution of 31% (SD = 14; d = 1.58, 95% CI = 0.76-2.40). This effect on auditory verbal hallucinations lasted for up to 3 months. Also, data analysis showed an improvement with tDCS of other symptoms as measured by the PANSS 33 (d = 0.98, 95% CI = 0.22-1.73), especially for the negative and positive dimensions. No effect was observed on the dimensions of disorganization or grandiosity/excitement.
Fitzgerald et al 36 conducted 2 double-blind controlled trials comparing bimodal tDCS with sham stimulation to investigate the effects on negative and cognitive symptoms of SCZ. Twenty-four patients (17 with SCZ and 7 with a diagnosis of schizoaffective disorder with persistent hallucinations and negative symptoms of SCZ, received 15 daily sessions of 2-mA tDCS or sham stimulation for 3 consecutive weeks. 11 subjects received bilateral and 13 subjects received unilateral stimulation. Anodal stimulation was applied to the prefrontal cortex and cathodal stimulation was applied to the temporoparietal junction. All subjects were assessed using the PANSS, 33 the SANS, 34 and the Calgary Depression Scale for Schizophrenia (CDSS). 41 Moreover, a cognitive performance was assessed (forward and backward digit span, block spatial span tests, N-back task, Tower of London planning task, FAS verbal fluency task, and the trail making task). Results did not demonstrate any therapeutic effects of tDCS in auditory hallucination or in the severity of positive and negative symptoms.
Gomes et al 37 reported their findings from a randomized, double blind, controlled trial on negative symptoms of adult patients with SCZ (N = 15). These patients were stimulated once a day for 10 days for 20 minutes, with a direct current of 2.0 mA for 20 minutes. The cathode was placed over the right DLPFC and the anode over the left DLPFC.
Patients were randomized into 2 groups: 7 active and 8 sham. Clinical outcomes were assessed by the PANSS, 33 CDSS, 41 and Global Assessment of Functioning (GAF). 42 After stimulation, patients who received the active stimulation showed reduced PANSS 33 negative, general, and total scores. The percentages of changes in the negative, general, and total scores due to the interaction between time and group were 45.4%, 29%, and 42.3%, respectively. No effects were observed for depression scores, functional outcomes or for positive symptoms. In addition, no significant differences were found for the sham group in any variable.
Using the same electrode placement, Shiozawa et al 38 investigated the effect of the concomitant use of tDCS and cognitive training over clinical symptoms in a small sample of adult patients with SCZ (N = 10). All patients were using atypical antipsychotic medication. The primary outcome of this study was to assess a possible improvement in cognitive performance. Psychotic symptoms (global, negative, positive, and general symptoms) of SCZ were considered as secondary outcomes and were assessed with the PANSS. 33 The tDCS protocol consisted of 10 consecutive sessions over 5-day periods, with a minimum interval of 3 hours between sessions. Cognitive training was based on the administration of N-back and sequence learning tasks, which were randomly applied during one of the tDCS sessions. The tests were computerized to easy repeated administration. All patients reported mild transient paresthesia over the stimulated area. No other adverse effect was reported. The findings reveal baseline PANSS 33 scores were related to final results (P = .001). In addition, the use of cognitive therapy combined with tDCS showed no relation with changes in clinical scores. However, the use of cognitive therapy combined with tDCS showed no relation with changes in clinical scores. Finally, mixed analysis of variance indicated no statistical significance between the groups regarding final PANSS 33 scores. Overall, in this small sample of adult patients with SCZ, the concomitant use of tDCS and cognitive training would not be effective to improve clinical outcomes (eg, cognitive performance, level of global, positive, negative, and general symptoms) in patients with SCZ. Finally, Palm et al, 39 conducted a double-blind, sham-controlled, proof-of-concept study to investigate the effect of tDCS in paranoid or disorganized SCZ patients with predominantly negative symptoms (N = 20). The subjects were randomized to receive 20 minutes of active 2-mA tDCS or sham tDCS per day within 2 weeks. The anode was placed over the left DLPFC and the cathode over the right orbitofrontal region. Antipsychotic medication treatment (clozapine) was continue at stable doses during the study. Outcomes measure were taken 1 day before the first tDCS session (t0), after 5 tDCS session (t1), after 10 tDCS session (t2), and 4 weeks after first tDCS (t3). In particular, clinical outcomes were assessed with the SANS, 34 the PANSS, 33 the CDSS, 41 and Subjective Well-being under Neuroleptic Treatment Scale (SWN). 43 The Self-Ordered Pointing Task (SOPT) 44 and the trail making test 45 were used to assess cognitive outcomes. In addition, the Comfort Rating Questionnaire (CRQ) was used to assess safety during each tDCS session. Furthermore, a group of 16 patients was subjected to 4 fcMRI scans immediately before and after the 1st and 10th tDCS. Results showed, after active tDCS, a reduction of negative symptoms measured by SANS 34 scores (0.7%), in particular alogia dimension (40.9%), and by PANSS 33 scores (23.4%), especially in subscale of negative (30.8%) and depression/anxiety (19.3%) dimensions.
Discussion
There are promising results in the application of tDCS for the reduction of negative symptoms of SCZ. 37, 46 However, a number of these findings are based on open-label studies 46, 47 or case reports 48 and require confirmatory evidence in randomized, double-blinded, controlled design with large samples. For this reason, we focused our review on randomized double-blind trials examining the efficacy of tDCS on negative symptoms in SCZ.
Based on the present selected review on 5 studies, we found no clear confirmatory evidence, since only 3 of these studies demonstrated decrease of negative symptoms, while the other 2 studies did not show any therapeutic effects of tDCS in the severity of positive and negative symptoms compared with controls. Nevertheless, such contrasting findings may be due to differences in methodological issues which, we believe, have significant role in affecting the results.
The first factor concerns the tDCS electrode montages. As conceivable form literature and from small open-label and case study's findings, all trials focused on DLPFC brain target. However, among the 5 studies, there were 3 alternative tDCS electrode montages, representing different cathodal cortical targets. The first approach was a combined stimulation with anodal tDCS of the DLPFC (midway between F3 and FP1 or F3) and cathodal tDCS of the temporo-parietal junction (TPJ; midway between T3 and P3 or TP3 or TP4). This approach was used in the study by Brunelin et al 35 (for the left hemisphere) and in the study by Fitzgerald et al 36 (for both the left and right hemispheres). The approach was based on the assumption that focusing tDCS on these 2 regions, particularly with cathodal tDCS on the left TPJ, may reduce the severity of auditory hallucinations in SCZ. 39 Although the approach was not strictly focused on negative symptoms improvement, one of the studies 35 showed general improvement and positive findings in negative symptoms as well. Studies from the first approach, thus, showed contrasting findings. Nevertheless, the trials differed in a main methodological aspect concerning the timing of stimulation sessions. The first provided stimulation twice daily over a 5-day period, while the second provided once daily sessions for a period of 3 weeks, which is a method with more widely spaced individual sessions.
The second approach focused on anodal tDCS of the left DLPFC (F3) with cathodal tDCS over the right DLPFC (F4), and was used by Gomes et al 37 and Shiozawa et al. 38 This is the approach that has been considered of interest for the treatment of negative symptoms in SCZ. 37, 46 However, again, only 1 of the 2 trials following this second approach obtained positive findings and showed marked improvement of negative symptoms. 37 Moreover, again, there was a different methodological aspect concerning the timing of stimulation sessions between the studies, which was more spaced in the first 37 and less spaced in the second study. 38 Finally, the third approach focused on anodal tDCS of the left DLPFC (F3) and catodal tDCS of the right orbitofrontal cortex (Fp2), which emphasizes the facilitation of the left DLPF. This is in line with the second approach, being considered of interest for the treatment of negative symptoms in SCZ. The third approach was used by Palm et al 39 in patients with prevalent negative symptoms and the trial showed marked improvement on negative symptoms.
Summing up, inconsistent results between the five trials do not seem to be explained solely by the electrode montages factor, as divergent findings exist within the same montage approach.
A second factor that might have contributed to these divergent findings could be the spacing of tDCS sessions during the treatment. Indeed, studies within each approach differed in the frequency of sessions and this may be therapeutically significant. More intensive application of tDCS in motor cortex showed that repeated tDCS sessions at short interval may be more effective than single (or presumably more widely spaced individual) sessions. 49 It is, however, difficult to make conclusions as to the optimal spacing of tDCS sessions in the treatment of negative symptoms of SCZ, given that more intensive treatment in Shiozawa et al 38 did not lead to positive findings. Therefore, further research should address the optimal spacing of treatment sessions might prove to be useful for the improvement of negative symptoms in SCZ, in particular whether a more intensive treatment is really useful, taking into account clearly safety concerns.
A third factor, mostly neglected, that might have contributed to the contrasting results is the concurrent pharmacological treatment factor, which we believe is of primary importance to
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Clinical EEG and Neuroscience 49 (1) disentangle the tDCS results on SCZ treatment. A very recent study 50 demonstrated that the type of antipsychotic medication has a differential impact on tDCS effects. The dopaminergic system has been demonstrated to be critical for the neuromodulatory effects of tDCS. 51 Previous works have shown a nonlinear association between dopamine receptor activity and tDCS effects; both over-and underactivation of either D1-or D2-like receptors can block these effects. [52] [53] [54] Agarwal et al 50 found that the difference in clinical improvement between patients with SCZ using different drug type is due to a greater availability of the dopamine receptor system in patients taking drugs with low affinity to D2 receptors, or with transient occupation of D2 receptors, or which are partial agonist of D2 receptors (such as clozapine, olanzapine, aripiprazole, quetiapine), which in turn allows for the beneficial neuromodulatory effects of tDCS.
Additionally, this effect seems to be sex specific. Indeed, dopamine receptor system is more sensitive in women to antipsychotic medication (possibly due to potential estrogen effects) than in men. Likewise, estrogen is understood to have a facilitatory role in the generation of long-term potentiation, 55 a crucial mechanism for brain plasticity induced by tDCS.
The synergistic relationship between estrogen and dopamine could be another reason why the differential effects of tDCS were seen especially in females with SCZ and antipsychotic treatment.
Looking at the 5 trials examined, 2 of them 36, 37 did not give information about the concomitant antipsychotic treatment and we do not know whether the divergent results between these 2 studies are due to a differential affinity to D2 receptors of the antipsychotic drug used.
The study by Shiozawa et al 38 did not control for the type of antipsychotic treatment and included patents which were under treatment with several drugs, with both low and high affinities to D2 receptors, which might have contributed to their negative findings.
Two studies with stable antipsychotic drug treatment 35, 39 showed positive findings. Marked improvement of negative symptoms was shown in the study by Palm et al, 39 in which patients were under clozapine, an antipsychotic with high Ki values that bind to the D2 receptors only for a brief duration, enabling its normal physiological function. 56 Hence, contrasting findings between the 5 trials could probably be due to the interaction of the tDCS and the concomitant pharmacological treatment.
The fourth factor that should be taken into account to clarify differential results between the studies is the considerable degree of heterogeneity in the patient samples. Only one trial included patients with predominant negative symptoms and no gender balance was controlled between active and control groups. Finally, neuroimaging data are not available on the actual effects on brain activation after tDCS in the patients examined.
In conclusion, this selected review showed that negative symptoms in SCZ can be treated with tDCS over the DLPFC, but results are affected by several factors. Moreover, within the domains of negative symptoms, the functional contribution of the stimulation of DLPFC to this symptom cluster is still not fully elucidated 20, 21, 39 and neuroimaging data are required to clarify the issue.
Randomized, double-blinded, sham-controlled studies in large samples are still needed to establish the effectiveness of the tDCS treatment of SCZ and its negative symptoms. Future studies should control for the aforementioned factors, including only patients on stable medications, controlling the homogeneity of the samples, standardizing the frequency of the sessions, with the scope to maximize the effect of tDCS on negative symptoms. Although the effectiveness of tDCS treatment for negative symptoms in SCZ is still to be confirmed, tDCS has the potential to become a useful complementary treatment option in this population.
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